Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT-220F in mCRPC
NCT06866795Phase 1Not yet recruiting
- Sponsor
- Geode Therapeutics
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of GT-220F in metastatic castration-resistant prostate cancer (mCRPC) (6 arms), sponsored by Geode Therapeutics. Primary endpoints: Dose Limiting Toxicity, Maximum Tolerated Dose and 2 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
GT-220F
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06866795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866795.